Admin-Core-001
管理核心-001
基本信息
- 批准号:10496102
- 负责人:
- 金额:$ 18.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAIDS related cancerAcquired Immunodeficiency SyndromeAdenovirus VectorAdenovirusesAffectAfricaAfrica South of the SaharaAfricanAntibodiesAntibody RepertoireBiological AssayCOVID-19COVID-19 patientCOVID-19 preventionCOVID-19 vaccineCancer PatientCardiovascular DiseasesCase StudyChinaClinicalCollaborationsCommunicable DiseasesCoronavirusCountryDataDevelopmentDiabetes MellitusDiagnosisDiseaseDisease ProgressionElderlyEnrollmentEpidemicEquipmentExposure toHIVHIV InfectionsHIV SeropositivityHIV-1High PrevalenceHospitalsHumanHuman Herpesvirus 8Human ResourcesHuman papilloma virus infectionHypertensionImmuneImmune responseImmune systemImmunofluorescence ImmunologicIndividualInfectionInfectious AgentInflammationKaposi SarcomaKnowledgeLeukocytesLung diseasesMalignant NeoplasmsMeasuresOutcomeParticipantPathogenesisPlasmaPopulationRecoveryReportingResourcesRisk FactorsRoleSARS-CoV-2 antibodySARS-CoV-2 infectionSamplingSquamous Cell NeoplasmsSymptomsTeaching HospitalsTechniquesTechnologyTimeUniversitiesVirusZambiabasebed capacitycase controlcomorbiditycytokinedisorder riskfollow-uphigh riskhigh throughput analysishuman coronavirusimmunosuppressedinterestmortalitynasopharyngeal swabnext generationnovelocular surfaceocular surface squamous neoplasiapandemic diseasepotential biomarkerpreventprogramsreconstitutionrecruitresponsesevere COVID-19virology
项目摘要
Abstract
This application is submitted in response to the notice of special interest identified as CA-21-033. The SARS-
coronavirus-2 (SARS-CoV-2) has rapidly spread worldwide causing the global pandemic. There are a number
of comorbidities and risk factors associated with COVID-19 and cancer patients could be at higher risk since
they tend to be older, likely to have multiple comorbidities, and are often immunosuppressed. Cancer patients,
especially those who are HIV+, in sub-Saharan Africa (SSA) where HIV is still epidemic are at particularly
higher risk of disease since they may not be completely immune reconstituted. Our team has a long-term
collaboration with our Zambia partners to study cancer pathogenesis in conjunction with HIV. With the
increasing number of SARS-CoV-2 infection in Zambia, it is important to determine the effects of SARS-CoV-2
infection and COVID-19 in cancer patients with or without HIV. Our overall objective is to develop a better
understanding of potential synergistic effects of HIV, and prior exposure to other infectious diseases in cancers
patients on COVID-19 disease development in sub-Saharan Africa. This was suggested by our data showing
that the sub-Saharan Africa populations have exposures to a number of human coronaviruses prior to the
pandemic and may confer some cross-protective immune response against SARS-CoV-2 infection and
subsequent COVID-19, if infected. In addition, we now have preliminary data showing that there are differential
humoral immune responses against different infections between COVID-19 patients with and without cancers
and HIV, which will provide an avenue for us to further investigate the role of other infectious diseases in
COVID-19. Our secondary objective is to predict the efficacy of adenovirus-vector based SARS-CoV-2
vaccines through our high throughput analysis of the humoral immune responses against all potential
infections. We hypothesize that COVID-19 patients with prior exposure to other infectious diseases including
seasonal coronaviruses will have a more tempered COVID-19 disease course, but cancer and HIV infection in
COVID-19 patients will lead to less effective immune responses in controlling SARS-CoV-2 and affect their
disease courses. Our specific aims are: 1) To determine the relationships between COVID-19 with HIV and
other infectious diseases and cancer. 2) Longitudinal follow up of COVID-19 cases and controls on their
recovery to determine changes in their virological parameters, anti-SARS-CoV-2 humoral response, and
inflammation status. The proposed study is significant and timely because it will synergize with our ongoing
U54 project (ZAMDAPP) on HIV-associated malignancies. The results generated will help to determine
whether prior exposure to other infectious disease can affect the COVID-19 course differently in the high risk
HIV positive cancer patients in SSA, and may also predict the efficacy of adenovirus-vector based COVID-19
vaccines in the region. Our results will help predict the extent of COVID-19 course and prevent disease
progression in the HIV infected cancer patients in Zambia and beyond.
摘要
本申请是根据CA-21 - 033特别关注通知提交的。SARS-
冠状病毒-2(SARS-CoV-2)已经在世界范围内迅速传播,引起全球大流行。有许多
与COVID-19和癌症患者相关的合并症和风险因素的风险可能更高,
他们往往年龄较大,可能有多种合并症,并且经常受到免疫抑制。癌症患者,
特别是那些艾滋病毒阳性的人,在艾滋病毒仍然流行的撒哈拉以南非洲,
更高的疾病风险,因为他们可能没有完全免疫重建。我们的团队有一个长期的
与我们的赞比亚伙伴合作,研究癌症发病机制与艾滋病毒。与
随着赞比亚SARS-CoV-2感染人数的增加,确定SARS-CoV-2的影响很重要
感染和COVID-19的癌症患者或无艾滋病毒。我们的总体目标是发展一个更好的
了解艾滋病毒的潜在协同效应,以及癌症患者先前暴露于其他传染病
在撒哈拉以南非洲的COVID-19疾病发展中的患者。我们的数据显示,
撒哈拉以南非洲地区的人口在2010年之前曾接触过一些人类冠状病毒,
大流行,并可能赋予一些针对SARS-CoV-2感染的交叉保护性免疫应答,
随后的COVID-19,如果感染。此外,我们现在有初步数据显示,
2019冠状病毒病伴和不伴癌症患者对不同感染的体液免疫应答
和艾滋病毒,这将为我们提供一个途径,以进一步研究其他传染病的作用,
2019冠状病毒病。我们的第二个目标是预测基于腺病毒载体的SARS-CoV-2的疗效
通过我们对所有潜在的体液免疫应答的高通量分析,
感染.我们假设,先前暴露于其他传染病的COVID-19患者,包括
季节性冠状病毒将有一个更温和的COVID-19疾病过程,但癌症和艾滋病毒感染,
COVID-19患者将导致控制SARS-CoV-2的有效免疫应答降低,并影响其
疾病历程我们的具体目标是:1)确定COVID-19与艾滋病毒之间的关系,
其他传染病和癌症。2)COVID-19病例的纵向随访及其控制
恢复,以确定其病毒学参数、抗SARS-CoV-2体液应答的变化,以及
炎症状态。拟议的研究是重要和及时的,因为它将与我们正在进行的研究产生协同作用。
艾滋病毒相关恶性肿瘤U54项目(ZAMDAPP)。产生的结果将有助于确定
在高风险人群中,既往暴露于其他传染病是否会对COVID-19病程产生不同的影响
SSA中的HIV阳性癌症患者,也可以预测基于COVID-19的腺病毒载体的疗效
疫苗在该地区。我们的研究结果将有助于预测COVID-19病程的程度并预防疾病
艾滋病毒感染的癌症患者在赞比亚和其他地区的进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chipepo Kankasa其他文献
Chipepo Kankasa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chipepo Kankasa', 18)}}的其他基金
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
- 批准号:
10618999 - 财政年份:2022
- 资助金额:
$ 18.79万 - 项目类别:
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
- 批准号:
10405562 - 财政年份:2022
- 资助金额:
$ 18.79万 - 项目类别:
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
- 批准号:
10542913 - 财政年份:2022
- 资助金额:
$ 18.79万 - 项目类别:
The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
赞比亚艾滋病恶性肿瘤诊断和发病机制计划 (ZAMDAPP)
- 批准号:
9404820 - 财政年份:2017
- 资助金额:
$ 18.79万 - 项目类别:
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program Supplement
赞比亚艾滋病恶性肿瘤诊断和发病机制计划补充资料
- 批准号:
10381368 - 财政年份:2017
- 资助金额:
$ 18.79万 - 项目类别:
The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
赞比亚艾滋病恶性肿瘤诊断和发病机制计划 (ZAMDAPP)
- 批准号:
10242673 - 财政年份:2017
- 资助金额:
$ 18.79万 - 项目类别:
相似海外基金
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6566071 - 财政年份:2001
- 资助金额:
$ 18.79万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6423242 - 财政年份:2000
- 资助金额:
$ 18.79万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6504219 - 财政年份:2000
- 资助金额:
$ 18.79万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6303902 - 财政年份:1999
- 资助金额:
$ 18.79万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6297230 - 财政年份:1998
- 资助金额:
$ 18.79万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6263862 - 财政年份:1998
- 资助金额:
$ 18.79万 - 项目类别:
Search for specific modulators of the inflammatory resp onse in AIDS related cancer
寻找艾滋病相关癌症中炎症反应的特异性调节剂
- 批准号:
nhmrc : 960853 - 财政年份:1996
- 资助金额:
$ 18.79万 - 项目类别:
CARG - Research














{{item.name}}会员




